In 2023, Paul Lonergan faced a prolonged sore throat mystery that led to a startling discovery: a sizable tumor at the base of his tongue. Enduring a rigorous regimen of seven weeks of radiation and chemotherapy, Lonergan fought to eradicate the tumor. However, a subsequent liquid biopsy revealed lingering tumor fragments in his bloodstream, hinting at a potential cancer recurrence.
Subsequently, Lonergan underwent experimental immunotherapy and was declared cancer-free after successive liquid biopsies confirmed the absence of disease traces. This innovative cancer monitoring method, known as liquid biopsy, remains limited to clinical trials and high-cost private facilities in Canada, but there are optimistic prospects for wider accessibility.
Dr. Ramy Saleh of McGill University Health Centre foresees a revolutionary impact of liquid biopsies on disease surveillance, emphasizing its potential to transform cancer recurrence monitoring. A Toronto-based research team from the University Health Network (UHN) initiated a comprehensive five-year clinical trial named SHERLOCK to assess the utility of liquid biopsies in routine patient care.
Led by Dr. Lillian Siu, the study aims to provide liquid biopsies to over 7,000 cancer survivors to detect circulating tumor DNA signaling potential relapse. Through the project, researchers strive to identify early disease indicators in the blood before traditional diagnostic methods can detect them, enabling prompt intervention and improved treatment outcomes.
Notably, liquid biopsy technology, introduced about a decade ago, has evolved to facilitate precise cancer monitoring through blood tests, presenting a promising approach for early disease detection and treatment optimization. Ongoing research highlights its potential in detecting residual disease post-surgery and improving survival rates for various cancer types.
While the technology shows promise, ethical considerations and the need for periodic testing pose challenges. Liquid biopsies have shown both false positive and false negative results, necessitating careful interpretation and patient counseling. Despite its limitations, the growing interest in liquid biopsies underscores its potential as a valuable tool in cancer care.
The UHN clinical trial aims to provide critical data supporting the integration of liquid biopsies into routine cancer care, with the ultimate goal of benefiting a larger patient population. Dr. Siu remains optimistic about the trial’s outcomes, anticipating valuable insights that could pave the way for widespread adoption of liquid biopsies in cancer management by 2031.